Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

SHAREHOLDER ALERT: Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Aclaris Shareholders to Contact the Firm

Press Releases August 1, 2019

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire July 31, 2019

Shareholder Alert: Robbins Arroyo LLP Announces Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders

Business Wire July 31, 2019

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

PR Newswire July 31, 2019

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Business Wire July 31, 2019

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Press Releases July 31, 2019

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS

Business Wire July 31, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

GlobeNewswire July 31, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aclaris Therapeutics, Inc. (ACRS)

Press Releases July 31, 2019

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm

GlobeNewswire July 30, 2019

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Business Wire July 30, 2019

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint

GlobeNewswire July 30, 2019

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire July 30, 2019

Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation

PR Newswire July 26, 2019

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

GlobeNewswire July 24, 2019

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

GlobeNewswire July 24, 2019

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire July 23, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

GlobeNewswire July 22, 2019

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire July 16, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of (ACRS) Aclaris Therapeutics, Inc.

Press Releases July 10, 2019